应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TRAW TRAWS PHARMA
休市中 06-12 16:00:00 EDT
1.28
+0.01
+0.79%
盘后
0.9515
-0.33
-25.66%
19:53 EDT
最高
1.31
最低
1.25
成交量
59.62万
今开
1.28
昨收
1.27
日振幅
4.72%
总市值
1,939万
流通市值
1,326万
总股本
1,515万
成交额
76.94万
换手率
5.76%
流通股本
1,036万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Traws Pharma现金跑道延长至2027年第一季度;推进替代性流感抗病毒候选药物——SEC文件披露
美股速递 · 06-13 05:28
Traws Pharma现金跑道延长至2027年第一季度;推进替代性流感抗病毒候选药物——SEC文件披露
Traws Pharma推迟Tivoxavir Marboxil计划中的2a期流感研究——基于英国MHRA的负面审评意见
美股速递 · 06-13 05:27
Traws Pharma推迟Tivoxavir Marboxil计划中的2a期流感研究——基于英国MHRA的负面审评意见
Traws Pharma宣布针对汉坦病毒及埃博拉病毒病疫情的抗病毒研发计划
美股速递 · 05-27
Traws Pharma宣布针对汉坦病毒及埃博拉病毒病疫情的抗病毒研发计划
Traws制药公司融资推进流感项目 将在英国开展Tivoxavir Marboxil人体挑战试验
美股速递 · 04-15
Traws制药公司融资推进流感项目 将在英国开展Tivoxavir Marboxil人体挑战试验
Traws Pharma, Inc.盘中异动 早盘大幅上涨5.10%报1.65美元
市场透视 · 02-20
Traws Pharma, Inc.盘中异动 早盘大幅上涨5.10%报1.65美元
Traws Pharma, Inc.股价重挫21.57% 市值跌266.3万美元
市场透视 · 02-19
Traws Pharma, Inc.股价重挫21.57% 市值跌266.3万美元
TRAWS PHARMA:美国FDA计划于3月16日前正式传达其关切及建议缓解措施
美股速递 · 02-19
TRAWS PHARMA:美国FDA计划于3月16日前正式传达其关切及建议缓解措施
Traws药业完成Ratutrelvir在适用与不适用Paxlovid®的新冠患者中的临床研究分析,并更新Tivoxavir Marboxil作为季节性流感预防性治疗的附加适应症
美股速递 · 02-19
Traws药业完成Ratutrelvir在适用与不适用Paxlovid®的新冠患者中的临床研究分析,并更新Tivoxavir Marboxil作为季节性流感预防性治疗的附加适应症
Traws Pharma, Inc.盘中异动 大幅上涨5.36%报2.07美元
市场透视 · 02-18
Traws Pharma, Inc.盘中异动 大幅上涨5.36%报2.07美元
Traws Pharma, Inc.盘中异动 早盘股价大跌5.69%报1.82美元
市场透视 · 02-11
Traws Pharma, Inc.盘中异动 早盘股价大跌5.69%报1.82美元
Traws药业完成Ratutrelvir在适用与不适用Paxlovid®的新冠患者中的临床研究入组;宣布计划为Tivoxavir Marboxil新增季节性流感预防性治疗适应症
美股速递 · 01-26
Traws药业完成Ratutrelvir在适用与不适用Paxlovid®的新冠患者中的临床研究入组;宣布计划为Tivoxavir Marboxil新增季节性流感预防性治疗适应症
Traws Pharma, Inc.盘中异动 急速下挫5.59%
市场透视 · 01-15
Traws Pharma, Inc.盘中异动 急速下挫5.59%
Traws Pharma Inc:Ratutrelvir展现出与Paxlovid™的显著不同的特征,副作用更少且未出现病毒反弹
美股速递 · 2025-12-17
Traws Pharma Inc:Ratutrelvir展现出与Paxlovid™的显著不同的特征,副作用更少且未出现病毒反弹
TRAWS PHARMA公布Ratutrelvir与Paxlovid™对比的积极中期临床数据,显示对不适合使用Paxlovid患者的疗效
美股速递 · 2025-12-17
TRAWS PHARMA公布Ratutrelvir与Paxlovid™对比的积极中期临床数据,显示对不适合使用Paxlovid患者的疗效
Traws Pharma, Inc.盘中异动 股价大跌5.30%
市场透视 · 2025-03-10
Traws Pharma, Inc.盘中异动 股价大跌5.30%
Traws Pharma, Inc.盘中异动 快速拉升5.05%
市场透视 · 2025-03-06
Traws Pharma, Inc.盘中异动 快速拉升5.05%
Traws Pharma, Inc.盘中异动 早盘股价大涨6.69%
市场透视 · 2025-03-05
Traws Pharma, Inc.盘中异动 早盘股价大涨6.69%
Traws Pharma, Inc.盘中异动 股价大跌6.95%
市场透视 · 2025-03-03
Traws Pharma, Inc.盘中异动 股价大跌6.95%
Traws Pharma, Inc.盘中异动 早盘大幅下挫5.17%
市场透视 · 2025-02-28
Traws Pharma, Inc.盘中异动 早盘大幅下挫5.17%
Traws Pharma, Inc.盘中异动 大幅拉升10.00%报3.85美元
市场透视 · 2025-02-26
Traws Pharma, Inc.盘中异动 大幅拉升10.00%报3.85美元
加载更多
公司概况
公司名称:
TRAWS PHARMA
所属市场:
NASDAQ
上市日期:
--
主营业务:
Traws Pharma, Inc.于1998年12月22日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,专注于开发针对呼吸道病毒性疾病的新型疗法。其研发管线包括用于流感和新冠病毒的候选抗病毒药物,以及通过先前合并获得的肿瘤学项目。在2024年4月合并后,公司的业务重点从癌症扩展至包括抗病毒药物开发。
发行价格:
--
{"stockData":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.28,"timestamp":1781294400000,"preClose":1.27,"halted":0,"volume":596197,"hourTrading":{"tag":"盘后","latestPrice":0.9515,"preClose":1.28,"latestTime":"19:53 EDT","volume":436130,"amount":429255.032137,"timestamp":1781308421826,"change":-0.3285,"changeRate":-0.256641,"amplitude":0.325781},"delay":0,"changeRate":0.007874015748031503,"floatShares":10358000,"shares":15150700,"eps":-1.520743,"marketStatus":"休市中","change":0.01,"latestTime":"06-12 16:00:00 EDT","open":1.28,"high":1.31,"low":1.25,"amount":769398.0712306,"amplitude":0.047244,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.520743,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.27,"preHourTrading":{"tag":"盘前","latestPrice":1.2795,"preClose":1.27,"latestTime":"09:24 EDT","volume":19003,"amount":24433.409397699997,"timestamp":1781270662582,"change":0.0095,"changeRate":0.00748,"amplitude":0.015669},"postHourTrading":{"tag":"盘后","latestPrice":0.9515,"preClose":1.28,"latestTime":"19:53 EDT","volume":436130,"amount":429255.032137,"timestamp":1781308421826,"change":-0.3285,"changeRate":-0.256641,"amplitude":0.325781},"volumeRatio":1.92707276022792,"impliedVol":1.6331,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TRAW","defaultTab":"news","newsList":[{"id":"1133310742","title":"Traws Pharma现金跑道延长至2027年第一季度;推进替代性流感抗病毒候选药物——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1133310742","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133310742?lang=zh_cn&edition=full","pubTime":"2026-06-13 05:28","pubTimestamp":1781299696,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会(SEC)的文件,Traws Pharma公司已将其现金跑道成功延长至2027年第一季度。这一财务上的里程碑为公司核心研发管线的推进提供了更为稳固的支撑。\n与此同时,公司正在积极推动其替代性流感抗病毒候选药物的研发进程。这些候选药物旨在应对现有流感治疗方案可能存在的局限,代表了公司在抗病毒领域的前沿探索。\n充足的资金保障与研发项目的同步推进,为Traws Pharma下一阶段的发展奠定了关键基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199034090","title":"Traws Pharma推迟Tivoxavir Marboxil计划中的2a期流感研究——基于英国MHRA的负面审评意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1199034090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199034090?lang=zh_cn&edition=full","pubTime":"2026-06-13 05:27","pubTimestamp":1781299635,"startTime":"0","endTime":"0","summary":"Traws Pharma公司已决定推迟其候选药物Tivoxavir Marboxil原定的2a期流感临床研究计划。这一决定是在英国药品和健康产品管理局(MHRA)对该研究方案给出负面审评意见后作出的。相关信息已通过公司提交给美国证券交易委员会(SEC)的文件予以披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143693038","title":"Traws Pharma宣布针对汉坦病毒及埃博拉病毒病疫情的抗病毒研发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1143693038","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143693038?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:48","pubTimestamp":1779886120,"startTime":"0","endTime":"0","summary":"生物制药公司Traws Pharma近日公布了一项新的抗病毒研发计划,该计划旨在应对当前仍在持续的汉坦病毒与埃博拉病毒病疫情。公司表示,此举是其针对重大公共卫生威胁扩大研发管线战略的一部分。汉坦病毒主要通过啮齿动物传播,可导致肾综合征出血热等严重疾病;而埃博拉病毒病则以其高死亡率和对公共卫生系统的巨大冲击而闻名。Traws Pharma的研发团队正致力于探索具有创新作用机制的候选化合物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133486290","title":"Traws制药公司融资推进流感项目 将在英国开展Tivoxavir Marboxil人体挑战试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1133486290","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133486290?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:17","pubTimestamp":1776255454,"startTime":"0","endTime":"0","summary":"Traws制药公司近日宣布获得新一轮融资,这笔资金将专项用于推进其流感治疗项目。公司计划在美国开展Tivoxavir Marboxil的人体挑战试验,这标志着该创新药物的研发进程取得重要突破。\n人体挑战试验作为一种高效的研究方法,能加速评估药物在真实感染环境下的安全性与有效性。Tivoxavir Marboxil作为公司流感管线的核心候选药物,此次试验结果将为后续临床开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613995122","title":"Traws Pharma, Inc.盘中异动 早盘大幅上涨5.10%报1.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613995122","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613995122?lang=zh_cn&edition=full","pubTime":"2026-02-20 22:49","pubTimestamp":1771598978,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日22时49分,Traws Pharma, Inc.股票出现波动,股价急速拉升5.10%。截至发稿,该股报1.65美元/股,成交量1.4331万股,换手率0.18%,振幅7.64%。Traws Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.24%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家临床阶段的生物制药公司,致力于开发新型疗法,以针对呼吸道病毒性疾病对人类健康的关键威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022022493897a69459&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022022493897a69459&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612253949","title":"Traws Pharma, Inc.股价重挫21.57% 市值跌266.3万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612253949","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612253949?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:31","pubTimestamp":1771511472,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日22时31分,Traws Pharma, Inc.股票出现波动,股价急速下跌21.57%。Traws Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.34%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家临床阶段的生物制药公司,致力于开发新型疗法,以针对呼吸道病毒性疾病对人类健康的关键威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219223112a70a7ccf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219223112a70a7ccf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177154585","title":"TRAWS PHARMA:美国FDA计划于3月16日前正式传达其关切及建议缓解措施","url":"https://stock-news.laohu8.com/highlight/detail?id=1177154585","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177154585?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:32","pubTimestamp":1771504331,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)已向TRAWS PHARMA公司表明,其计划在3月16日之前,就相关事宜正式传达其监管关切。此次沟通将不仅明确指出FDA所关注的问题,还将附带一系列建议的缓解步骤,旨在为该公司提供明确的指引路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101675571","title":"Traws药业完成Ratutrelvir在适用与不适用Paxlovid®的新冠患者中的临床研究分析,并更新Tivoxavir Marboxil作为季节性流感预防性治疗的附加适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1101675571","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101675571?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:31","pubTimestamp":1771504277,"startTime":"0","endTime":"0","summary":"Traws药业已成功完成其候选药物Ratutrelvir针对适用与不适用Paxlovid®治疗的新冠肺炎患者的临床研究数据分析。此项分析为评估该药物在不同患者群体中的疗效与安全性提供了关键见解。\n同时,公司宣布更新其另一款药物Tivoxavir Marboxil的研发进展,该药物正在寻求作为季节性流感的预防性治疗新适应症。这一进展标志着Traws药业在抗病毒治疗领域同时推进多项研发计划,旨在应对新冠病毒和季节性流感带来的公共卫生挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612547862","title":"Traws Pharma, Inc.盘中异动 大幅上涨5.36%报2.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612547862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612547862?lang=zh_cn&edition=full","pubTime":"2026-02-18 22:30","pubTimestamp":1771425059,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日22时30分,Traws Pharma, Inc.股票出现异动,股价快速上涨5.36%。Traws Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家临床阶段的生物制药公司,致力于开发新型疗法,以针对呼吸道病毒性疾病对人类健康的关键威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218223059a7077554&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218223059a7077554&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNSE","TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610851910","title":"Traws Pharma, Inc.盘中异动 早盘股价大跌5.69%报1.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610851910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610851910?lang=zh_cn&edition=full","pubTime":"2026-02-11 23:50","pubTimestamp":1770825012,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日23时50分,Traws Pharma, Inc.股票出现波动,股价快速下跌5.69%。截至发稿,该股报1.82美元/股,成交量1.9131万股,换手率0.24%,振幅5.66%。Traws Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.77%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家临床阶段的生物制药公司,致力于开发新型疗法,以针对呼吸道病毒性疾病对人类健康的关键威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211235012a6ef9df6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211235012a6ef9df6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112787706","title":"Traws药业完成Ratutrelvir在适用与不适用Paxlovid®的新冠患者中的临床研究入组;宣布计划为Tivoxavir Marboxil新增季节性流感预防性治疗适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1112787706","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112787706?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:32","pubTimestamp":1769434340,"startTime":"0","endTime":"0","summary":"Traws药业已顺利完成其候选药物Ratutrelvir针对适用及不适用Paxlovid®的新冠病毒感染者的临床试验患者招募工作。\n与此同时,该公司宣布将拓展其另一款药物Tivoxavir Marboxil的适应症范围,计划将其开发为季节性流感的预防性治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603603079","title":"Traws Pharma, Inc.盘中异动 急速下挫5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603079?lang=zh_cn&edition=full","pubTime":"2026-01-15 01:14","pubTimestamp":1768410894,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日01时14分,Traws Pharma, Inc.股票出现波动,股价快速下挫5.59%。Traws Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.07%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家临床阶段的生物制药公司,致力于开发新型疗法,以针对呼吸道病毒性疾病对人类健康的关键威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115011454953ccbb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115011454953ccbb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105664831","title":"Traws Pharma Inc:Ratutrelvir展现出与Paxlovid™的显著不同的特征,副作用更少且未出现病毒反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1105664831","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105664831?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:12","pubTimestamp":1765969962,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc:Ratutrelvir展现出与Paxlovid™的显著不同的特征,副作用更少且未出现病毒反弹","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177639705","title":"TRAWS PHARMA公布Ratutrelvir与Paxlovid™对比的积极中期临床数据,显示对不适合使用Paxlovid患者的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1177639705","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177639705?lang=zh_cn&edition=full","pubTime":"2025-12-17 19:12","pubTimestamp":1765969951,"startTime":"0","endTime":"0","summary":"TRAWS PHARMA公布Ratutrelvir与Paxlovid™的对比数据,展示其在不适合使用Paxlovid的COVID-19患者中具有积极的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518475278","title":"Traws Pharma, Inc.盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518475278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518475278?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:22","pubTimestamp":1741616551,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时22分,Traws Pharma, Inc.股票出现波动,股价快速跳水5.30%。Traws Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.47%。其相关个股中,Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃,换手率分别为3401.51%、720.06%、414.27%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc,振幅分别为41.36%、40.24%、39.34%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家生物制药公司,专注于开发流感、COVID和其他呼吸道感染的抗病毒药物和narazaciclib。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022223196404282&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022223196404282&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517161983","title":"Traws Pharma, Inc.盘中异动 快速拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517161983?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:13","pubTimestamp":1741274023,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时13分,Traws Pharma, Inc.股票出现异动,股价急速上涨5.05%。Traws Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.32%。其相关个股中,Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Plus Therapeutics, Inc.涨幅较大,Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃,换手率分别为1510.12%、905.97%、76.46%,振幅较大的相关个股有Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Moolec Science Sa C/Wts ,振幅分别为56.82%、44.64%、44.44%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家生物制药公司,专注于开发流感、COVID和其他呼吸道感染的抗病毒药物和narazaciclib。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306231343963c5603&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306231343963c5603&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517910578","title":"Traws Pharma, Inc.盘中异动 早盘股价大涨6.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517910578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517910578?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185027,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分,Traws Pharma, Inc.股票出现波动,股价急速拉升6.69%。Traws Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。其相关个股中,Klotho Neurosciences Inc C/Wts 21/06/2029 、Chimerix, Inc.、Silexion Therapeutics Corp涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Zyversa Therapeutics, Inc.较为活跃,换手率分别为310.54%、251.30%、183.65%,振幅较大的相关个股有4D Molecular Therapeutics, Inc.、Plus Therapeutics, Inc.、Zura Bio Limited,振幅分别为8.56%、6.59%、5.61%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家生物制药公司,专注于开发流感、COVID和其他呼吸道感染的抗病毒药物和narazaciclib。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223027963adbe6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223027963adbe6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516632682","title":"Traws Pharma, Inc.盘中异动 股价大跌6.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632682","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516632682?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:34","pubTimestamp":1741012446,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时34分,Traws Pharma, Inc.股票出现异动,股价大幅下跌6.95%。Traws Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.38%。其相关个股中,Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Alto Neuroscience, Inc.涨幅较大,Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Bioxcel Therapeutics, Inc.较为活跃,换手率分别为47.66%、28.93%、27.72%,振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Spruce Biosciences, Inc.,振幅分别为33.98%、21.22%、19.25%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家生物制药公司,专注于开发流感、COVID和其他呼吸道感染的抗病毒药物和narazaciclib。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223406989a1018&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223406989a1018&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514515373","title":"Traws Pharma, Inc.盘中异动 早盘大幅下挫5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514515373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514515373?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:05","pubTimestamp":1740755127,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时05分,Traws Pharma, Inc.股票出现波动,股价快速跳水5.17%。Traws Pharma, Inc.股票所在的生物技术行业中,整体涨幅为0.31%。其相关个股中,Bioxcel Therapeutics, Inc.、Immunitybio, Inc.、Puma Biotechnology Inc涨幅较大,Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃,换手率分别为1009.23%、385.75%、319.45%,振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Bioxcel Therapeutics, Inc.,振幅分别为46.60%、42.89%、38.73%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家生物制药公司,专注于开发流感、COVID和其他呼吸道感染的抗病毒药物和narazaciclib。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228230527a25809d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228230527a25809d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514851333","title":"Traws Pharma, Inc.盘中异动 大幅拉升10.00%报3.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514851333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514851333?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:07","pubTimestamp":1740582421,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时07分,Traws Pharma, Inc.股票出现异动,股价快速上涨10.00%。截至发稿,该股报3.85美元/股,成交量1503股,换手率0.04%,振幅10.00%。Traws Pharma, Inc.股票所在的生物技术行业中,整体跌幅为0.08%。Traws Pharma, Inc.公司简介:Traws Pharma Inc 是一家生物制药公司,专注于开发流感、COVID和其他呼吸道感染的抗病毒药物和narazaciclib。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226230701abddf581&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226230701abddf581&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trawspharma.com","stockEarnings":[{"period":"1week","weight":-0.0657},{"period":"1month","weight":-0.2558},{"period":"3month","weight":-0.36},{"period":"6month","weight":-0.4506},{"period":"1year","weight":-0.2889},{"period":"ytd","weight":0.1327}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Traws Pharma, Inc.于1998年12月22日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,专注于开发针对呼吸道病毒性疾病的新型疗法。其研发管线包括用于流感和新冠病毒的候选抗病毒药物,以及通过先前合并获得的肿瘤学项目。在2024年4月合并后,公司的业务重点从癌症扩展至包括抗病毒药物开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.179894},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.08728},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.040526},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.139367},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.053691},{"month":6,"riseRate":0.692308,"avgChangeRate":0.052778},{"month":7,"riseRate":0.25,"avgChangeRate":-0.019463},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.120142},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.103896},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.080722},{"month":11,"riseRate":0.461538,"avgChangeRate":-0.058331},{"month":12,"riseRate":0.307692,"avgChangeRate":0.009577}],"exchange":"NASDAQ","name":"TRAWS PHARMA","nameEN":"TRAWS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRAWS PHARMA(TRAW)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TRAWS PHARMA(TRAW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TRAWS PHARMA,TRAW,TRAWS PHARMA股票,TRAWS PHARMA股票老虎,TRAWS PHARMA股票老虎国际,TRAWS PHARMA行情,TRAWS PHARMA股票行情,TRAWS PHARMA股价,TRAWS PHARMA股市,TRAWS PHARMA股票价格,TRAWS PHARMA股票交易,TRAWS PHARMA股票购买,TRAWS PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRAWS PHARMA(TRAW)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TRAWS PHARMA(TRAW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}